Trial Profile
A PHASE I STUDY OF ERY974 AS A SINGLE AGENT IN PATIENTS WITH GPC3-POSITIVE ADVANCED SOLID TUMORS
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs ERY 974 (Primary) ; Tocilizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 18 Oct 2022 Planned End Date changed from 31 Dec 2022 to 30 Jun 2024.
- 16 Dec 2021 Status changed from planning to not yet recruiting.
- 12 Aug 2016 New trial record